Skip Navigation
  • Toggle Search
  • Landos Biopharma on Twitter
Landos Biopharma
  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Clinical Advisory Board
    • Contact Us
  • Product Candidates
    • Clinical Pipeline
    • Preclinical Candidates
    • Clinical Trials
  • Science
    • LANCE Precision Medicine Platform
    • Immuno–metabolic Pathways
    • Publications
  • Investors/Media
    • Investor/Media Home
    • Press Releases
    • Events & Presentations
    • Analyst Coverage
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investors/Media FAQs
  • Careers
    • Why Landos?
    • Open Positions
Identifying novel pathways at the interface of immunity and metabolism

Clinical Trials

Clinical Trials

Information on Landos Biopharma’s studies of omilancor (BT-11), NX-13 and LABP-104 are available at ClinicalTrials.gov (external link opens in a new window).

Drug Study Phase
OmilancorGlobal Phase 2 Ulcerative Colitis study (external link opens in a new window)
OmilancorGlobal Phase 2 Crohn’s disease study (external link opens in a new window)
NX-13Global Phase 1b Ulcerative Colitis study (external link opens in a new window)
LABP-104Phase 1 Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) study (external link opens in a new window)
shield-outline-white
shield-2
NO ALT
Landos Biopharma, Inc.
1800 Kraft Drive, Suite 216
Blacksburg, VA 24060
info@landosbiopharma.com (email link opens in email client)
(540) 218-2232 (phone link opens in phone dialer)
  • Site Map
  • Terms of Use
  • Privacy Policy

©2022 Landos Biopharma All Rights Reserved.

Schema